LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles
LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.
/ 80 items
#LLY↓
LifeMD Offers Lowest Cash-Pay Price for Wegovy & Ozempic at $199/Month
LifeMD now provides the lowest nationwide cash-pay price for Wegovy and Ozempic at $199/month for new patients, supporting more affordable access to GLP-1 weight-loss treatments.
Novo Nordisk, Eli Lilly Deny Mangoceuticals Partnership
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.
Citi Boosts Eli Lilly Price Target to $1,500 on Strong Weight Loss Outlook
Citi raises Eli Lilly’s price target to $1,500, citing growing dominance in the weight loss market after a Medicare and Medicaid access deal and over $40B in potential peak sales.
Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy
Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.
Novo Nordisk Shares Jump 3% After Withdrawing from $10 Billion Metsera Bidding War
Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.